Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F),...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Acquir Immune Defic Syndr
Glavni autori: Pozniak, Anton, Arribas, Jose R., Gathe, Joseph, Gupta, Samir K., Post, Frank A., Bloch, Mark, Avihingsanon, Anchalee, Crofoot, Gordon, Benson, Paul, Lichtenstein, Kenneth, Ramgopal, Moti, Chetchotisakd, Ploenchan, Custodio, Joseph M., Abram, Michael E., Wei, Xuelian, Cheng, Andrew, McCallister, Scott, SenGupta, Devi, Fordyce, Marshall W.
Format: Artigo
Jezik:Inglês
Izdano: JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Teme:
Clinical Science
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804743/
https://ncbi.nlm.nih.gov/pubmed/26627107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000000908
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items